Pay in 4 interest-free payments of $5.59 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
JAMA 330 , 14721483 (2023)
doi:10.3945/jn.108.095273
Every patient is screened before any peptide is prescribed
It is important to recognise that tiredness can arise from multiple factors, including the underlying condition being treated (type 2 diabetes itself), changes in eating patterns due to reduced appetite, gastrointestinal side effects affecting nutrition, or concurrent medications
Summary Keywords Alzheimers disease, clinical trial, cognitive dysfunction, GLP-1 receptor agonist, neuroinflammation, neuroprotection, semaglutide, vascular dementia Citation Alhowail AH, Al Mouslem AK, Almatrafi MA and Aldubayan MA (2026) Semaglutide in cognitive dysfunction: neuroprotective potential, clinical trial limitations, and a prevention-focused framework
US$ 20.56
US$ 26.86
US$ 25.99
US$ 21.69
US$ 20.62
US$ 26.81
US$ 21.44
US$ 24.28
US$ 22.45
